NFE2L2 and breast carcinoma: Rong et al. reported that sulforaphane blocked prostaglandin E2 synthesis in parental and doxorubicin-resistant breast cancer 4T1 cell lines by activating NRF2, and triggered MDSCs to switch to an immunogenic phenotype, enhancing the anti-tumor activities of CD8+ T cells [34].